APOC2 and non-small cell lung carcinoma: Thus, we hypothesized that the inhibition of lactyl‐APOC2‐K70 by APOC2 lactyl‐K70 antibody or inhibition of lactate by FX11 (an LDHA inhibitor)[43] might significantly promote immunotherapy in NSCLC.